Related Experiment Video
Updated: Jun 29, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
ADRA2A polymorphism and smoking in a Turkish population
B Karahalil1, E Coskun, E Emerce
1Department of Toxicology, Faculty of Pharmacy, Gazi University, Ankara, Turkey. bensuka@gmail.com
Toxicology and Industrial Health
|October 10, 2008
Summary
This study investigated the ADRA2A C1291G gene polymorphism in 203 Turkish individuals, finding allele frequencies of 64% C and 36% G. The G allele showed a potential association with smoking predisposition.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Molecular Biology
Background:
- Adrenoceptors (ARs) are crucial for physiological functions and drug targets.
- Genetic variations in ARs, including the ADRA2A gene, can lead to polymorphism.
- The ADRA2A C1291G polymorphism influences neurotransmitter release, blood pressure, and other key functions.
Purpose of the Study:
- To determine the allelic and genotypic frequencies of the ADRA2A C1291G polymorphism in the Turkish population.
- To investigate the potential association between the ADRA2A C1291G polymorphism and smoking habits in this cohort.
Main Methods:
- Genotyping of 203 healthy Turkish subjects for the ADRA2A C1291G polymorphism.
- Analysis of allele and genotype distributions.
- Statistical evaluation for association with smoking status.
Main Results:
- Allele frequencies in the Turkish population were 64% for 1291C and 36% for 1291G.
- Genotype frequencies were 35.5% (C/C), 57.6% (C/G), and 6.9% (G/G).
- A slight increase in the G allele frequency was observed in smokers compared to non-smokers.
Conclusions:
- The ADRA2A C1291G polymorphism distribution in Turkish Caucasians is comparable to other Caucasian populations.
- The ADRA2A G allele may be associated with an increased predisposition to smoking.
- Further studies on genotype and haplotype variations are warranted to confirm these findings and explore their clinical significance.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...